IP Library › Granted Patent US 7,041,290
Granted Patent B2
US 7,041,290 · App. 10/718,321 · Granted May 9, 2006

Molecules and methods for inhibiting shedding of KIM-1

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,041,290
App. No.
10/718,321
Granted
May 9, 2006
Kind
B2
Abstract

Disclosed are antibodies that inhibit proteolytic release of a soluble KIM-1 polypeptide from KIM-1 expressing cells. Also disclosed are methods of using the antibodies to inhibit shedding of the KIM-1 polypeptide.

Claims (40)

1. An isolated monoclonal antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within or overlapping the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).

2. An isolated antibody or antigen-binding-fragment thereof that has the same epitope specificity as the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

3. An isolated antibody or antigen-binding-fragment thereof that crossblocks binding of the antibody produced by the hybridoma deposited in the ATCC under Accession No. PTA-3350.

4. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the monoclonal antibody is a humanized antibody.

5. The isolated antibody or antigen-binding-fragment thereof of claim 1 , wherein the monoclonal antibody is a fully human antibody.

6. A conjugate comprising the isolated antibody or antigen-binding fragment thereof of claim 1 , 2 or 3 linked to a detectable label.

7. A conjugate or fusion polypeptide comprising the isolated antibody or antigen-binding fragment thereof of claim 1 , 2 or 3 and a toxin moiety.

8. An antibody produced by the hybridoma deposited with ATCC under Accession No. PTA-3350.

9. Hybridoma ABE3, deposited with ATCC under Accession No. PTA-3350.

10. A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 1 , 2 or 3 and a pharmaceutically acceptable carrier.

11. An isolated antibody or antigen-binding fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7 at an epitope within the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO: 1).

12. The isolated antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody is a humanized antibody.

13. The isolated antibody or antigen-binding fragment thereof of claim 3 , wherein the antibody is a humanized antibody.

14. The isolated antibody or antigen-binding fragment thereof of claim 11 , wherein the antibody is a humanized antibody.

15. The isolated antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody is a fully human antibody.

16. The isolated antibody or antigen-binding fragment thereof of claim 3 , wherein the antibody is a fully human antibody.

17. The isolated antibody or antigen-binding fragment thereof of claim 11 , wherein the antibody is a fully human antibody.

18. The isolated antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody is a monoclonal antibody.

19. The isolated antibody or antigen-binding fragment thereof of claim 3 , wherein the antibody is a monoclonal antibody.

20. The isolated antibody or antigen-binding fragment thereof of claim 11 , wherein the antibody is a monoclonal antibody.

21. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the monoclonal antibody is a single chain antibody.

22. The isolated antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody is a single chain antibody.

23. The isolated antibody or antigen-binding fragment thereof of claim 3 , wherein the antibody is a single chain antibody.

24. The isolated antibody or antigen-binding fragment thereof of claim 11 , wherein the antibody is a single chain antibody.

25. The isolated antibody or antigen-binding fragment thereof of claim 1 , wherein the monoclonal antibody or antigen-binding fragment thereof is a chimeric antibody, an F ab fragment, an F (ab′)2 fragment, an F ab′ fragment, an F sc fragment, or an F v fragment.

26. The isolated antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F ab fragment, an F (ab′)2 fragment, an F ab′ fragment, an F sc fragment, or an F v fragment.

27. The isolated antibody or antigen-binding fragment thereof of claim 3 , wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F ab fragment, an F (ab′)2 fragment, an F ab′ fragment, an F sc fragment, or an F v fragment.

28. The isolated antibody or antigen-binding fragment thereof of claim 11 , wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F ab fragment, an F (ab′)2 fragment, an F ab′ fragment, an F sc fragment, or an F v fragment.

29. An isolated antibody or antigen-binding-fragment thereof that binds to the extracellular domain of the human KIM-1 polypeptide of SEQ ID NO:7, when expressed on the surface of a cell, at an epitope within or overlapping the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO:1).

30. The isolated antibody or antigen-binding fragment thereof of claim 29 , wherein the antibody is a humanized antibody.

31. The isolated antibody or antigen-binding fragment thereof of claim 29 , wherein the antibody is a fully human antibody.

32. The isolated antibody or antigen-binding fragment thereof of claim 29 , wherein the antibody is a monoclonal antibody.

33. The isolated antibody or antigen-binding fragment thereof of claim 29 , wherein the antibody is a single chain antibody.

34. The isolated antibody or antigen-binding fragment thereof of claim 29 , wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F ab fragment, an F (ab′)2 fragment, an F ab′ fragment, an F sc fragment, or an F v fragment.

35. The isolated antibody or antigen-binding fragment thereof of claim 29 , wherein the antibody or antigen-binding fragment thereof binds to an epitope within the amino acid sequence: SSDGLWNNNQTQLFLEHS (SEQ ID NO: 1).

36. The isolated antibody or antigen-binding fragment thereof of claim 29 , wherein the antibody is a humanized antibody.

37. The isolated antibody or antigen-binding fragment thereof of claim 35 , wherein the antibody is a fully human antibody.

38. The isolated antibody or antigen-binding fragment thereof of claim 35 , wherein the antibody is a monoclonal antibody.

39. The isolated antibody or antigen-binding fragment thereof of claim 35 , wherein the antibody is a single chain antibody.

40. The isolated antibody or antigen-binding fragment thereof of claim 35 , wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, a chimeric antibody, an F ab fragment, an F (ab′)2 fragment, an F ab′ fragment, an F sc fragment, or an F v fragment.

Assignments (1)
CHANGE OF NAME Recorded May 4, 2015
From: BIOGEN IDEC MA INC.
To: BIOGEN MA INC.
Reel/Frame 035571/0926 →